Join
Live feed
·
PRReleasevia Quantisnow
Aurinia Pharmaceuticals Inc logo

Aurinia Announces Positive Topline Results From the AURORA 2 Continuation Study of LUPKYNIS™ (voclosporin) for the Treatment of Adults With Active Lupus Nephritis (LN)

ByQuantisnow·Wall Street's wire, on your screen.
AUPH· Aurinia Pharmaceuticals Inc
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track AUPH (Aurinia Pharmaceuticals Inc) and more on Quantisnow.